KBC Group’s Nuvation Bio NUVB Stock Holding History

KBC Group’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49K	Hold	8,699	–	–	﹤0.01%	1715
2026 Q1	$37K	Buy	+8,699	New	+$48.5K	﹤0.01%	1748

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

KBC Group's NUVB Position: Q2 2026 in Review

KBC Group held its Nuvation Bio (NUVB) position steady in Q2 2026 at 8,699 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #1715.

KBC Group first reported a position in NUVB in Q1 2026 and has held it in 2 quarters since. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

KBC Group held 8,699 shares of Nuvation Bio worth $49K as of Q2 2026.
KBC Group left its Nuvation Bio share count unchanged in Q2 2026.
Nuvation Bio made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1715 holding.
KBC Group first reported a position in Nuvation Bio in Q1 2026 and has held it in 2 quarters since.
244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.